// App-Quantinova.ai

2049 : Results of a Phase I Trial of Lenalidomide, Rituximab (R2) and Ixazomib for Frontline Treatment of High Risk Follicular and Indolent Non-Hodgkin Lymphoma

Researchers

Presenter

  • Brian T. Hill

Principal Investigators

  • Deepa Jagadeesh

  • Alex V. Mejia Garcia

  • Robert M. Dean

  • Omer N. Koc

  • Matt Kalaycio

  • Kirsten M Boughan

  • Brenda W. Cooper

  • Allison M. Winter

  • Wesam B. Ahmed

  • Brad Pohlman

  • Christopher D'Andrea

  • Kelsey Holkovic

  • Ashley Morrison

  • Paolo Caimi

  • Mitchell R Smith

Medical Centers

  • Taussig Cancer Institute, Department of Hematology and Medical Oncology, Cleveland Clinic, Cleveland, OH

  • Taussig Cancer Institute, Department of Hematology and Medical Oncology, Cleveland Clinic, Cleveland, OH

  • Taussig Cancer Institute, Department of Hematology and Medical Oncology, Cleveland Clinic, Cleveland, OH

  • Taussig Cancer Institute Cleveland Clinic, Cleveland, OH

  • University Hospital Seidman Cancer Center, Cleveland, OH

  • Adult Hematologic Malignancies & Stem Cell Transplant Program, University Hospitals, Seidman Cancer Center, Cleveland, OH

  • Florida, Cleveland Clinic, Weston, FL

  • George Washington University Cancer Center, Washington, DC

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Venous thrombosis

  • Non-Hodgkin's Lymphoma

  • Non‐Hodgkin Lymphoma

  • B-Cell Non-Hodgkin Lymphoma

  • Hodgkin's Lymphoma

  • Lymphomas

Biomarkers

  • N/A

Drug/Treatment

  • Lenalidomide

  • Rituximab

  • Acyclovir

  • Ixazomib

  • Aspirin

  • Albyl-E

Outcome

  • N/A

Study Design

  • Dose Escalation

Phase

  • I

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved